These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 22284868

  • 1. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R.
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
    Martin R.
    Neurodegener Dis; 2008 Jan; 5(1):23-6. PubMed ID: 18075271
    [Abstract] [Full Text] [Related]

  • 4. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
    Neurology; 2007 Aug 21; 69(8):785-9. PubMed ID: 17709711
    [Abstract] [Full Text] [Related]

  • 5. Daclizumab in treatment of multiple sclerosis patients.
    Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ.
    Mult Scler; 2009 Feb 21; 15(2):272-4. PubMed ID: 19136546
    [Abstract] [Full Text] [Related]

  • 6. Daclizumab (anti-CD25) in multiple sclerosis.
    Pfender N, Martin R.
    Exp Neurol; 2014 Dec 21; 262 Pt A():44-51. PubMed ID: 24768797
    [Abstract] [Full Text] [Related]

  • 7. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
    Immunotherapy; 2010 Jul 21; 2(4):437. PubMed ID: 20635996
    [No Abstract] [Full Text] [Related]

  • 8. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
    Osherov M, Milo R.
    Expert Rev Clin Pharmacol; 2017 Oct 21; 10(10):1037-1047. PubMed ID: 28803486
    [Abstract] [Full Text] [Related]

  • 9. In vivo maintenance of human regulatory T cells during CD25 blockade.
    Huss DJ, Mehta DS, Sharma A, You X, Riester KA, Sheridan JP, Amaravadi LS, Elkins JS, Fontenot JD.
    J Immunol; 2015 Jan 01; 194(1):84-92. PubMed ID: 25416807
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
    Sheridan JP, Zhang Y, Riester K, Tang MT, Efros L, Shi J, Harris J, Vexler V, Elkins JS.
    Mult Scler; 2011 Dec 01; 17(12):1441-8. PubMed ID: 21807759
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J.
    N Engl J Med; 2015 Oct 08; 373(15):1418-28. PubMed ID: 26444729
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J, Wang L, Zhan S, Tan J, Xia Y.
    Cochrane Database Syst Rev; 2010 Jun 16; (6):CD008127. PubMed ID: 20556791
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
    Baldassari LE, Rose JW.
    Neurotherapeutics; 2017 Oct 16; 14(4):842-858. PubMed ID: 28707278
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.